U.S. judge rejects Amgen bid to block biosimilar Neupogen

March 19, 2015 8:01 PM

2 0

U.S. judge rejects Amgen bid to block biosimilar Neupogen

SAN FRANCISCO (Reuters) - A U.S. judge on Thursday denied Amgen Inc's bid to block the sale of Novartis AG's recently approved "biosimilar" form of Neupogen, Amgen's blockbuster drug used to prevent infections in cancer patients.

In his ruling, U.S. District Judge Richard Seeborg, of San Francisco federal court, denied Amgen's request for a preliminary injunction to prevent Novartis' Sandoz unit from launching its copycat. The drug, Zarxio, contains the same active ingredient as Amgen's $1.2 billion-a-year Neupogen, and once...

Read more

To category page

Loading...